Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review

Abstract

Chronic spontaneous urticaria (CSU) is a condition in which wheals, angioedema, and pruritus occur spontaneously and recurrently for at least 6 weeks. The etiology of this disease is partially dependent on production of autoantibodies that activate and recruit inflammatory cells. Although the wheals can resolve within 24 h, symptoms have a significant detrimental impact on the quality of life of these patients. Standard therapy for CSU includes second-generation antihistamines and omalizumab. However, many patients tend to be refractory to these therapies. Available treatments such as cyclosporine, dapsone, dupilumab, and tumor necrosis factor alpha (TNFa) inhibitors have been used with success in some cases. Furthermore, various biologics and other novel drugs have emerged as potential treatments for this condition, and many more are currently under investigation in randomized clinical trials.

Key Summary Points

Chronic spontaneous urticaria is a debilitating disease that can negatively impact quality of life

Few therapies are approved for this condition, and patients can be refractory to these treatments

In this article, we highlight the various novel drugs that are currently being studied in clinical trials for this disease

Introduction

Chronic urticaria is characterized by wheals, angioedema, or both that occur continuously or sporadically for at least 6 weeks. The wheals are intensely pruritic, resolve in < 24 h, and tend to recur on a daily basis [1]. Chronic urticaria typically lasts for 2–5 years before spontaneously resolving [2]. The point prevalence of the disease ranges from 0.23 to 0.70% in different studies, and it most commonly affects women [3, 4]. Pruritus in these patients frequently occurs on a daily basis, with many patients reporting increased itching at night. It most commonly occurs on the back, upper extremities, and lower extremities and is often accompanied by a heat sensation [5]. Chronic urticaria can cause physical and emotional functional impairments as well as sleep disturbances, fatigue, and irritability due to pruritus, leading to significantly reduce quality of life in these patients [6]. Patients have also been shown to suffer from psychiatric comorbidities such as anxiety, depression, and somatoform disorders at higher rates than controls [7].

Chronic urticaria can be further classified as chronic inducible urticaria (CIU), in which symptoms are evoked by temperature changes or pressure, or chronic spontaneous urticaria (CSU), in which lesions occur spontaneously [1]. The pathogenesis of CSU is thought to involve an autoimmune component that can be characterized by the presence of IgE autoantibodies (type I or autoallergic) or IgG autoantibodies (type IIb) [8]. Both of these endotypes involve mast cell activation, which is the hallmark of the disease and leads to vasodilation, recruitment of inflammatory cells, and sensory neural activation [8]. Other mechanisms are also thought to play a role in the etiology of CSU, including alterations in the coagulation cascade, vitamin D deficiency, and infections [9]. d-dimer levels have been suggested to be a biomarker of CSU severity and may help clinicians in decision making about escalating to more aggressive treatment with biologics or higher medication doses [10, 11].

While guidelines that contain a stepwise treatment algorithm with mainstay CSU therapies were recently published, a myriad of drugs have emerged as effective treatments for CSU, and many more are currently under investigation [12]. In this review, we will discuss available treatments for CSU as well as novel therapies that could provide promising outcomes.

Methods

A literature review was performed on PubMed to retrieve relevant English-language articles on the mentioned chronic spontaneous urticaria treatments between 2010 and 2023. The national clinical trial database ClinicalTrials.gov was used to obtain information regarding any ongoing clinical trials. References and citations from retrieved articles were also assessed to obtain other relevant literature. The considered relevant papers were accessed and included in the review. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Current and Available Treatments

Second-Generation H1-Antihistamines (sgAHs)

Second-generation H1-antihistamines (sgAHs) such as loratadine, desloratadine, cetirizine, and levocetirizine are the first-line treatment for CSU. These are preferred over first-generation antihistamines for they selectively block peripheral receptors, therefore causing fewer side effects, including sedation and anticholinergic effects [9]. In general, no significant differences are seen between the different sgAHs in controlling CSU symptoms [13]. Standard doses of antihistamines may not provide relief for many CSU patients, however, with a recent study reporting a response rate of only 38.6% [14]. Guidelines recommend that the dose should be increased up to fourfold in patients who do not adequately respond to standard doses, with bilastine, fexofenadine, levocetirizine, and cetirizine having good-quality evidence for up-dosing [12, 15]. Dose escalation by two- or four-fold has been shown to lead to complete remission in 63.2% of CSU cases [14]. Furthermore, a cohort study of 175 pediatric chronic urticaria patients showed that 92% of cases were well controlled with sgAHs, and these medications were found to have a favorable safety profile in randomized controlled trials (RTCs) evaluating children [16–18]. The addition of a second sgAH or another medication such as a H2-antihistamine or leukotriene receptor antagonist (LTRA) can also be considered in certain cases [19]. The addition of LTRA montelukast to first-line therapy with sgAHs, for example, was found to be particularly effective in patients with angioedema-predominant CSU, leading to disease resolution in about two-thirds of cases [20].

Omalizumab

Omalizumab is a recombinant humanized monoclonal antibody against IgE that was approved by the Food and Drug Administration (FDA) for the treatment of antihistamine-refractory CSU. It works by binding to free IgE and inhibiting interaction with the FcεRI receptor on basophils and mast cells, thus preventing their activation (Fig. 1). It also increases free IgE levels, leading to downregulation of FcεRI receptors [9]. Many RTCs have been conducted to evaluate the efficacy of omalizumab in CSU patients. One meta-analysis including seven trials reported that patients treated with omalizumab had significantly reduced itch scores and wheal scores compared to placebo, with the strongest reduction in weekly itch scores seen in those taking 300 mg every 4 weeks [21]. Improvements in quality of life are also seen with this therapy, with one systematic review reporting an improvement of 13.12 points on a scale of 23–115 using the validated chronic urticaria quality of life questionnaire [22].

Fig. 1.

Mechanism of action of some existing and novel therapies for chronic spontaneous urticaria

The response to treatment may vary depending on a patient’s disease endotype. Patients with type I CSU who have IgE autoantibodies against allergens such as thyroperoxidase (TPO) usually respond quickly and effectively to omalizumab. A RTC assessing patients who had antihistamine-refractory CSU and IgE anti-TPO reported that 70.4% of patients demonstrated complete protection from wheal development compared to 4.5% in the placebo group, and complete absence of pruritus was seen in 59.3% of patients compared to 9.1% of controls [23]. Those with type IIb CSU are less likely to respond to omalizumab and have delayed onset of response to the drug [8]. Many studies have shown that patients who partially respond to the standard dose of 300 mg every 4 weeks can benefit from dose increases [24]. Omalizumab is generally well tolerated, and the most common adverse effects include injection site reactions, viral infections, upper respiratory infections, sinusitis, and headaches [25]. Patient monitoring is often recommended after the first three doses of the drug because anaphylaxis—although rare—is more likely to occur within this time frame [26]. In the last 2 years, the FDA has also approved home self-administration of omalizumab [27].

Cyclosporine

Cyclosporine is an immunosuppressant that has been used as an off-label add-on therapy in patients who are refractory to monotherapy with antihistamines or omalizumab [9]. A meta-analysis evaluating efficacy of cyclosporine in CSU revealed a significant change from baseline in mean urticaria activity score (which measures the intensity of wheals and pruritus) for those taking cyclosporine compared to placebo [28]. However, Savic et al. found that omalizumab was superior to cyclosporine in disease resolution and quality of life improvements [29]. Patients with biomarkers indicative of type IIb CSU were found to have quicker and more favorable response to cyclosporine [30]. There are a variety of adverse effects associated with this agent, including nausea, vomiting, headaches, hypertension, and nephrotoxicity, and many of these are dose-dependent. Although most side effects resolve with dose reduction, they have been shown to lead to treatment discontinuation in up to 18.1% of CSU patients [28].

Other immunosuppressants

Other immunosuppressants such as methotrexate (MTX), azathioprine, and mycophenolate mofetil (MMF) have been used off-label to treat CSU. MTX did not demonstrate efficacy as an add-on treatment to antihistamines in randomized clinical trials [31–33]. Azathioprine has been shown to reduce chronic urticaria symptoms and was reported to be efficacious in patients with refractory CSU [34, 35]. Furthermore, small studies have shown that MMF improved urticarial symptoms in 88% of patients with CSU and that it significantly decreased the number of wheals and itch severity in patients refractory to antihistamines and corticosteroids [36, 37].

Dapsone

Dapsone is a sulfone antibiotic that has been used to treat various dermatologic conditions, and its anti-inflammatory properties could be helpful in treating CSU. In a small open study of 11 refractory CSU patients, 9 patients experienced a complete response after 3 months of treatment with dapsone and cetirizine [38]. The effect of dapsone has been reported to last as long as 1 year, with a case report showing no recurrence in CSU symptoms despite discontinuation of all treatments [39]. Treatment with dapsone for 6 weeks showed a significant reduction in both itch and visual analog scale (VAS) ratings of urticaria severity compared to placebo in a cohort of antihistamine-refractory patients. However, only 3 out of 22 patients showed complete resolution of pruritus and hives with this therapy [40]. A retrospective chart review by Liang et al. found that 78% of patients with CSU improved with dapsone therapy, and 44% of these patients achieved complete response after a mean time of 5.2 months. Adverse effects were mild and most commonly included reticulocytosis and anemia [41]. Furthermore, a recent systematic review and meta-analysis found that treatment with dapsone resulted in a large increase in clinical improvement, although it caused little to no difference in remission rates [42]. The authors of these studies concluded that dapsone is an effective second-line treatment modality in CSU patients.

Hydroxychloroquine

Hydroxychloroquine (HCQ) is an antimalarial drug that is useful in managing some autoimmune and inflammatory conditions. Although its mechanism of action in CSU is not well understood, several studies have shown it can reduce symptoms in these patients. A study evaluating antihistamine-refractory CSU patients found that 20.8% of patients who received hydroxychloroquine daily in addition to H1-antihhistamines experienced disease remission at 12 weeks compared to no patients achieving remission in the placebo group (antihistamines only) [43]. Furthermore, there were significant improvements in severity scores and quality of life in those treated with HCQ compared to placebo. However, no significant difference was found in urticarial severity scores or urticarial responses between HCQ and a leukotriene receptor antagonist in a follow-up study [43]. Other studies have also found that HCQ improves the quality of life in CSU [44]. A recent retrospective chart review including a cohort of 264 refractory CSU patients found that although omalizumab add-on therapy was associated with a higher rate of complete response, 66% of patients on HCQ achieved complete, sustained disease response at 1 year. No retinal abnormalities were found on serial visual field testing in those treated with HCQ. Therefore, the study found that HCQ is an acceptable alternative to omalizumab, especially due to its lower cost [45].

Intravenous immunoglobulin (IVIG)

IVIG is a polyvalent antibody product derived from plasma of healthy donors. Its various effects on the immune system include inactivating autoreactive T cells, downregulating B-cell antibody production, and blocking FcεR-mediated activity (Fig. 1) [46]. IVIG has been used in the treatment of autoimmune disorders and was proposed for treatment of refractory CSU by O’Donnell et al., who reported significant improvement in urticaria activity scores after IVIG treatment compared to baseline [47]. In another case series, administration of IVIG led to remission after 12 months in four out of six patients. Many of these patients experienced a decrease in urticaria activity score after 1–3 cycles of treatment. Adverse effects included headache, chills, fever, and increased blood pressure [46]. Another study found that 73% of patients had complete remission of symptoms with use of IVIG every 4 weeks, although the number of infusions needed to achieve disease control varied widely between patients [48]. However, no randomized clinical trials have evaluated the efficacy of this therapy in CSU patients, and more robust data are needed to support its use.

Autologous serum therapy

Autologous serum therapy (AST) involves injecting a patient’s own serum subcutaneously or intramuscularly (IM). Studies have showed mixed results in the efficacy of IM AST in patients with a positive autologous serum skin test (ASST). In a study with 66 CSU patients, AST therapy led to significant improvement in disease activity after 8 weeks [49]. However, another prospective study found that, after 12 weeks, only 12% of patients experienced partial or complete remission with this therapy [50]. Subcutaneous AST has been reported to significantly decrease urticarial activity scores (UAS) and to improve quality of life in CSU patients [51, 52].

Dupilumab

Inhibition of Th2 cytokines such as interleukin (IL)-4, IL-5, and IL-13 leads to decreased IgE production and limited activation of mast cells and basophils, all of which play a role in CSU pathogenesis. Dupilumab is a monoclonal antibody against IL-4/13Rα that has been used off-label for the treatment of CSU. It has been shown to be effective within 3 months in patients with refractory CSU, with a case series reporting that 67% of patients started on dupilumab remained in remission after treatment discontinuation [53]. Results from a phase III RTC show that patients on a standard dose of antihistamines who received add-on dupilumab reported significant changes in itch severity scores and urticaria activity scores compared to those treated with antihistamine monotherapy [54]. Other RTCs to further evaluate dupilumab efficacy and safety in CSU patients are currently ongoing, and further studies are needed to assess dupilumab therapy in omalizumab-refractory patients [8, 9].

Rituximab

Rituximab is a monoclonal antibody against CD20 on B cells and has been proposed as an alternative therapy in CSU patients because of its potential ability to inhibit IgG autoantibodies against FcεRI or IgE [55]. There have been several case reports in which rituximab has been successfully used to treat refractory CSU [56–58].One phase I/II open-label trial aimed to assess rituximab use in these patients but was terminated because of safety concerns [9]. Currently, more data are needed to support the use of this drug in CSU patients.

TNFa Inhibitors

Mast cell activation leads to the release of various inflammatory mediators, including TNFa. TNFa production is increased in CSU patients, and these patients also have increased TNFa expression in both lesional and nonlesional skin compared to healthy controls [59, 60]. Furthermore, serum levels of TNFa are positively correlated to disease severity assessed by the UAS [61]. TNFa inhibitors such as etanercept and adalimumab commonly used for psoriasis have been tried off-label in CSU patients. One retrospective study reported 60% of patients had complete or almost complete symptom resolution after treatment with TNFa inhibitors, and many had sustained responses with a mean of 13 months [62]. TNFa inhibitors have also been used to successfully treat immunosuppressive-refractory CSU patients, and even led to disease remission in three out of six cases [63]. However, RTCs with a larger study population are needed to provide a better assessment of the efficacy and safety of these agents in CSU.

Secukinumab

IL-17 is implicated in cutaneous diseases such as psoriasis, and it may also play a role in the pathogenesis of CSU. Levels of this cytokine were found to be elevated in the serum of CSU patients and correlated with disease activity [64, 65]. IL-17 is also highly expressed in both lesional and nonlesional skin of CSU patients compared to controls, with increased IL-17A expression observed in skin mast cells [66]. This indicates that IL-17 may contribute to the increased mast cell degranulation seen in this disease. Secukinumab, an IL-17 inhibitor, was used to treat eight patients who were refractory to standard CSU treatments. The intensity of wheals and pruritus—measured by the urticaria activity score—was significantly reduced by 55% from baseline after 30 days, and by 82% after 90 days, and patients remained in remission throughout the duration of therapy [66]. More studies evaluating this drug in CSU patients are warranted.

Novel Therapies and Therapies Under Development

Anti-IgE Monoclonal Antibodies: Ligelizumab, UB221

Ligelizumab is a novel humanized monoclonal anti-IgE antibody that works by binding to IgE with a much higher affinity than omalizumab. It has been shown that this drug is more potent than omalizumab at suppressing free IgE levels and at reducing expression of FcεRI and IgE on basophils [67]. A phase IIb study evaluated three doses of ligelizumab (24 mg, 72 mg, and 240 mg) and found that this drug achieved complete symptom control in up to 44% of CSU patients by week 12 compared to 26% of patients taking omalizumab [68]. Furthermore, the percentage of patients achieving a weekly itch severity score of 0 was higher in all ligelizumab groups compared to omalizumab at week 12 [68]. An extension, open-label study was subsequently performed and demonstrated sustained efficacy of the drug, with 84.2% of patients having cumulatively achieved minimal disease activity by week 52 [69]. A multicenter phase III RTC evaluating the use of this drug in adolescents and adults with CSU and comparing ligelizumab with omalizumab has recently been completed. Preliminary data confirm the efficacy of ligelizumab in CSU patients compared to placebo, although it did not find this drug to be superior to omalizumab when assessing changes from baseline in urticaria activity scores at week 12 (NCT03580369, https://www.hcplive.com/view/phase-3-ligelizumab-not-superior-omalizumab). A phase III clinical trial evaluating the efficacy and safety of ligelizumab in CSU was recently terminated, but this was not due to safety concerns (NCT04210843). Ligelizumab was found to have a favorable safety profile, with the most common adverse events being injection site reactions, nasopharyngitis, headache, upper respiratory tract infection, and urticaria [69].

UB221 is a monoclonal antibody that binds to CD23-bound IgE, thus downregulating CD23-mediated IgE production. It also binds to IgE with higher affinity than omalizumab, with a rapid reduction in serum IgE observed after one IV dose of UB221 in mice models [70]. UB221 is currently under investigation in phase I and phase II studies as a potential add-on therapy for patients with CSU (Table 1) (NCT03632291, NCT05298215). Other RTCs evaluating the pharmacodynamics, pharmacokinetics, safety, and efficacy of UB221 are also underway (NCT04175704, NCT04404023).

Table 1.

Ongoing clinical trials in chronic spontaneous urticaria (www.clinicaltrials.gov)

Therapy	Mechanism of action	NCT#	Phase	Primary outcomes
Dupilumab	Monoclonal antibody against IL-4/13Rα	NCT05526521 NCT04180488	Phase 3 Phase 3	The concentration of dupilumab in serum over time Change from baseline in weekly itch severity score (ISS7) and weekly urticarial activity score (UAS7)
UB221	Monoclonal antibody against CD23-bound IgE	NCT05298215 NCT04175704 NCT04404023	Phase 2 Phase 1 Phase 1	Change in serum free IgE level from baseline over time To evaluate the safety of UB-221 in CSU patients The adverse event incidence from the baseline to day 15 after infusion
Remibrutinib	Bruton tyrosine kinase inhibitor	NCT05513001 NCT05677451 NCT05048342 NCT05032157 NCT05030311	Phase 3 Phase 3 Phase 3 Phase 3 Phase 3	Time to first composite event (i.e., relapse (UAS7 ≥ 16) Change from baseline in UAS7, ISS7, and weekly hives severity score (HSS7) The number and the proportion of participants with adverse events Change from baseline in UAS7 Change from baseline in UAS7
Rilzabrutinib	Bruton tyrosine kinase inhibitor	NCT05107115	Phase 2	Change from baseline in UAS7 and ISS7 at Week 12
Mepolizumab	Anti-IL5 monoclonal antibodies	NCT03494881	Phase 1	Mean UAS7
Benralizumab	Anti-IL5 monoclonal antibodies	NCT04612725	Phase 2	Change from baseline in ISS7 at Week 12
Tezepelumab	Anti-TSLP monoclonal antibody	NCT04833855	Phase 2	Change from baseline in UAS7
Lirentelimab	Anti-Siglec-8 monoclonal antibody	NCT05528861	Phase 2	Absolute change in UAS7 at Week 12
Barzolvolimab	Anti-KIT monoclonal antibody	NCT05368285	Phase 2	Mean change from baseline to Week 12 of UAS7

Bruton Tyrosine Kinase (BTK) inhibitors: Fenebrutinib, Remibrutinib, Rilzabrutinib

BTK is an enzyme involved in FcεRI-mediated mast cell activation, basophil signaling, and B-cell functioning. BTK inhibitors prohibit IgE-mediated responses and thus can be a useful therapy in CSU patients [8, 55]. Fenebrutinib is a highly selective BTK inhibitor that is given orally and was recently evaluated in a phase II RTC for treatment of antihistamine-resistant CSU. By week 8, improvements in urticarial activity scores were seen in patients randomized to 200 mg twice daily and 150 mg daily but not 50 mg daily compared to placebo. This response was dose-dependent, with 39% of patients taking 200 mg twice daily achieving complete response at week 8 compared to 25% of those taking 150 mg daily and 4% of those taking the placebo [71]. Adverse effects were minimal and most commonly included headache, urticaria, and nasopharyngitis [71]. Remibrutinib, another potent oral BTK inhibitor, was also found to improve antihistamine-resistant CSU symptoms in a phase II RTC. Multiple doses were tested, and all were found to significantly reduce urticaria activity symptom scores. Improvement was observed as early as week 1 and maintained through the end of the study at week 12 [72]. This agent was also shown to improve the quality of life in CSU patients, with significant improvements in Dermatology Life Quality Index (DLQI) scores observed at week 12 compared to placebo [73]. The efficacy and safety of BTK inhibitor rilzabrutinib are currently being assessed in a phase II RTC (NCT05107115).

Anti-IL5 Monoclonal Antibodies: Mepolizumab, Reslizumab, Benralizumab

Cutaneous eosinophilic infiltration secondary to mast cell recruitment via IL-5 may contribute to the pathogenesis of CSU, for these patients have increased eosinophils in both lesional and nonlesional skin compared to controls [74, 75]. Mepolizumab, an anti-IL5 monoclonal antibody, is approved for treatment of eosinophilic asthma and has been used off-label to treat CSU [76]. A current phase I open-label study is underway to assess the efficacy of 10 weeks of mepolizumab therapy in these patients (NCT03494881). Reslizumab, another monoclonal antibody that targets IL-5, led to sustained improvement in urticarial symptoms in a patient with angioedema-predominant CSU 4 weeks after starting treatment [77]. Furthermore, the anti-IL5 receptor antibody benralizumab has also been investigated as a potential therapy for CSU. Benralizumab was administered in 3 monthly injections to a cohort of 12 CSU patients who were refractory to antihistamines. After the three doses, the urticarial activity score decreased significantly by 15.7 points, and five patients achieved complete response at the end of the study [78]. In an ongoing phase II RTC, benralizumab induction and maintenance dosing regimens are being evaluated in a cohort of adult patients who were refractory to antihistamines (NCT04612725).

Tezepelumab

Thymic stromal lymphopoietin (TSLP) is a cytokine that promotes Th2 inflammation. TSLP expression was shown to be increased in lesional skin of patients with CSU, indicating it may play a role in the pathogenesis of the disease [79]. Therefore, blocking TSLP action with drugs such as the monoclonal antibody tezepelumab may be useful in reducing inflammation in CSU. The INCEPTION study, a phase II RTC evaluating the efficacy of tezepelumab in adult CSU patients compared to omalizumab and placebo, is currently underway but no results have been published (NCT04833855).

Lirentelimab

Sialic acid-binding, immunoglobulin-like lectin (Siglec)-8 is an inhibitory receptor selectively expressed on mast cells, basophils, and eosinophils (Fig. 1). Binding of monoclonal antibodies to this receptor leads to apoptosis of eosinophils and inhibition of FcεRI-mediated mast cell activation [80]. Due to its mechanism of action, lirentelimab, an anti-Siglec-8 monoclonal antibody, has been explored as a treatment for CSU. In a phase II study, both omalizumab-naïve and -resistant CSU patients were treated with intravenous infusions of lirentelimab. Patients experienced symptomatic improvement and decreases in urticaria activity scores from baseline at week 22. Furthermore, 95% of omalizumab-naïve and 46% of omalizumab-refractory CSU patients experienced complete response at week 22. The most common adverse events included infusion-related reactions, nasopharyngitis, and headache [81]. A study to assess subcutaneous liretenlimab in adult CSU patients is ongoing (NCT05528861).

AZD1981

Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) is a prostaglandin D2 (PGD2) receptor expressed on basophils, eosinophils, and some Th2 cells. By binding to CRTH2, PGD2—which is released by mast cells—leads to activation and chemotaxis of eosinophils and basophils [80]. Increased eosinophilic CRTH2 expression has been reported in allergic skin diseases, including chronic urticaria and atopic dermatitis [82]. However, Oliver et al. found decreased CRTH2 expression on blood basophils and eosinophils of CSU patients, which they speculated could be due to in vivo PGD2 activation [83]. The oral selective CRTH2 antagonist AZD1981 has been investigated in antihistamine-resistant CSU patients and was found to have a greater effect on weekly itch scores than on hives during a 4-week treatment period and into the washout period [84]. Treatment with AZD1981 was also found to increase circulating eosinophils and reduce PGD2-mediated eosinophil shape change [84]. More studies are needed to evaluate the long-term efficacy of this agent in CSU.

Barzolvolimab

The KIT receptor and its ligand stem cell factor (SCF) are important regulators of mast cell differentiation, maturation, and survival. Barzolvolimab is a monoclonal anti-KIT antibody and is a promising new treatment for CSU patients. A study in healthy human volunteers showed that barzolvolimab inhibits SCF-dependent mast cell activation and leads to systemic mast cell ablation [85]. A recently published abstract of an ongoing phase I clinical trial reported that CSU patients receiving IV barzolvolimab had dose-dependent improvements in urticarial activity score by week 8 of treatment [86]. A phase II study assessing this novel therapy in CSU patients is currently underway (NCT05368285).

GSK2646264

Spleen tyrosine kinase (Syk) is involved in signal transduction in various immune cells and plays an important role in FcεRI signaling and activation of mast cells [80]. The selective, topical Syk inhibitor GSK2646264 has been shown to decrease histamine release from skin mast cells, indicating that this therapy could potentially be used in CSU patients [87]. A phase I study evaluating GSK2646264 in healthy volunteers, cold urticaria, and CSU patients found that the drug was well tolerated but no conclusions could be made about changes in urticaria activity score due to the low number of CSU patients recruited [88]. More studies are needed to evaluate the efficacy of GSK2646264 in these patients.

Limitations

The main limitation of this narrative review is that it does not directly compare the efficacy of different treatment modalities between studies. Therefore, we are unable to provide data on which therapies are the most effective new treatments for CSU.

Conclusion

Chronic spontaneous urticaria is a debilitating disease that can negatively impact the quality of life of patients. Although antihistamines and omalizumab are the recommended therapies for this condition, many patients continue to experience hives and pruritus despite the use of these treatments. Many novel therapies are currently being investigated for use in CSU, and the results of some clinical trials show great promise. Overall, more studies are needed to assess the efficacy and safety of these emerging drugs.